ECMO in COVID-19-prolonged therapy needed? A retrospective analysis of outcome and prognostic factors.

ABSTRACT:

Background

The role of venovenous extracorporeal membrane oxygenation (VV ECMO) in patients with COVID-19-induced acute respiratory distress syndrome (ARDS) still remains unclear. Our aim was to investigate the clinical course and outcome of those patients and to identify factors associated with the need for prolonged ECMO therapy.

Methods

A retrospective single-center study on patients with VV ECMO for COVID-19-associated ARDS was performed. Baseline characteristics, ventilatory and ECMO parameters, and laboratory and virological results were evaluated over time. Six months follow-up was assessed.

Results

Eleven of 16 patients (68.8%) survived to 6 months follow-up with four patients requiring short-term (<28 days) and seven requiring prolonged (⩾28 days) ECMO suppor

SUBMITTER: Dreier E 

PROVIDER: S-EPMC8369905 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature